MYR Pharmaceuticals is pleased to announce the establishment of its wholly owned subsidiary MYR...
MYR Pharmaceuticals is a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis B (HBV) and D (HDV) infections. The company’s lead compound Bulevirtide (formerly known as Myrcludex B) is a first-in-class entry inhibitor for treatment of chronic HBV and HDV and is currently in a Phase 3 study in the indication of chronic HDV.
We are proud that our medicine has received:
- The Orphan Drug Designation from the European Medicines Agency (EMA) and U.S. Food & Drug Administration (FDA)
- PRIority MEdicines (PRIME) scheme eligibility (EMA)
- Breakthrough Therapy designation (FDA)
- Promising Innovative Medicine (PIM) designation from the British Medicines and Healthcare products Regulatory Agency (MHRA)